Therefore, the reversible modulation of insulin, as well as leptin receptor phosphorylation and signaling, holds significant clinical promise, highlighting the potential of PTP1B inhibition to reduce insulin resistance, restore glycemic balance, and target both type 2 diabetes and obesity [36,38]. The gene discussed is INS; the disease is obesity disorder.